•  2
    A phase II randomized, controlled trial of S-adenosylmethionine in reducing serum α-fetoprotein in patients with hepatitis C cirrhosis and elevated AFP
    with T. R. Morgan, K. Osann, T. Bottiglieri, N. Pimstone, J. C. Hoefs, K. Q. Hu, T. Hassanein, T. D. Boyer, L. Kong, W. P. Chen, E. Richmond, L. M. Rodriguez, and F. L. Meyskens
    © 2015 American Association for Cancer Research. In animal models of hepatocellular carcinoma, deficiency of S-adenosylmethionine increased the risk of HCC whereas administration of SAMe reduced HCC. The aim of this trial was to determine whether oral SAMe administration to patients with hepatitis C cirrhosis would decrease serum a-fetoprotein level, a biomarker of HCC risk in hepatitis C. This was a prospective, randomized, placebo-controlled, double-blind trial of SAMe, up to 2.4 g/d, for 24 w…Read more